Consolidated Financial Summary (IFRS) Fiscal 2026 Third Quarter
Filed with TSE · · 24 pages · English
Story so far
Earlier from Kyowa Kirin
- Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome
- Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America
- Kyowa Kirin Announces Agreement with U.S. Administration to Reduce Treatment Costs for Americans
- Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2026 Semi Annual
- European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union
Follow Kyowa Kirin into a list and get an email when it puts out news.
Follow Kyowa Kirin